The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF Live Webinar: Development of Novel and Targeted Agents in Precision Cancer Prevention and Interception

The Cancer Drug Development Forum (CDDF) held a live webinar on “Development of Novel and Targeted Agents in Precision Cancer Prevention and Interception” on Thursday 15 June 2023 at 5PM (CEST) / 11AM (EDT). This webinar was composed of Dr. Brian Cholewa (NCI,US)’s 25-minute presentation and a 30-minute discussion session moderated by Prof. Jaap Verweij (CDDF, NL) & Prof. Kim Lyerly (Duke University, US). This opened insightful, informative discussion on the topic which would be examined and explored further at the 2023 AAADV-ASCO-CDDF Workshop on Global Cancer Drug Development (13-15 September, 2023).


Drug development in cancer prevention and interception has numerous challenges that are unique in the oncology space. Some of the most notorious hurdles include defining high-risk populations, limiting drug-related toxicities and the extensive follow-up periods required to demonstrate efficacy. This talk will address those issues and discuss the U.S. National Cancer Institute’s initiatives that aim to resolve them.

Agenda: (CEST time zone)

17:00 – 17:05     Introduction – Jaap Verweij (CDDF,NL)

17:05 – 17:30     Presentation – Brian Cholewa (NCI,US)

17:30 – 18:00     Discussion – moderated by Jaap Verweij (CDDF, NL) & Kim Lyerly (Duke University, US)

Brian Cholewa

Brian Cholewa is a Senior Toxicologist and Program Director for the Chemopreventive Agent Development Research Group of the National Cancer Institute (NCI). Dr. Cholewa currently leads regulatory efforts for the Division of Cancer Prevention in support of the Cancer Prevention Clinical Trials Network and serves as the primary toxicologist for agent development in the PREVENT program. Dr. Cholewa completed his Ph.D. in Molecular and Environmental Toxicology at the University of Wisconsin – Madison, which was followed by a Postdoctoral Fellowship at Vanderbilt University Medical Center. Following a brief transition into industry, Dr. Cholewa joined the FDA as a Pharmacology/Toxicology Reviewer in the Division of Hematology Oncology Toxicology in the Office of Oncologic Diseases. He served as the primary toxicology reviewer on multiple New Drug Applications (NDAs) and hundreds of research and commercial Investigational New Drug Applications (INDs) prior to joining the NCI in the Spring of 2020.

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70